Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Should You Buy?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $18.90, but opened at $19.74. Daiichi Sankyo shares last traded at $19.74, with a volume of 457 shares changing hands.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Daiichi Sankyo presently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Down 2.3%

The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The company has a market cap of $34.57 billion, a P/E ratio of 21.58, a PEG ratio of 2.59 and a beta of -0.11. The firm’s 50-day simple moving average is $17.63 and its 200 day simple moving average is $17.26.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.